Corporate News

18 September 2017

Biosilu Healthcare AG and Glycotope GmbH signed term sheet for the development and commercialization of FSH-GEX® (follitropin epsilon) for China.

Frankfurt, September 18, 2017 - The life science company Biosilu Healthcare AG (ISIN DE000A0SMU87), listed on the Munich Stock Exchange, announced today the signing of a term sheet defining the framework of a future license and collaboration agreement between Biosilu Healthcare and Glycotope, a biopharmaceutical company based in Berlin. The framework agreement comprises China including Hong Kong and Macau. Financial details have not been disclosed.

Read More
17 September 2017

Biosilu's new corporate presentation available

The new corporate presentation of Biosilue Healthcare is available for download.

Read More
21 July 2017

Biosilu Healthcare AG: Annual report 2016

The Biosilu Healthcare AG publishes its annual report 2016, which has been approved by the supervisory board today.

Read More
11 July 2017

Biosilu Healthcare AG: capital increase by up to 8.7% fully subscribed

The Biosilu Healthcare AG fully subscribed a capital increase by up to 8.7% at a placement price of EUR 2.78 per share. The gross issuance volume is EUR 500,400.00.

Read More
11 July 2017

Biosilu Healthcare AG resolves capital increase

The Biosilu Healthcare AG resolves a capital increase by up to 8.7% from authorized capital to increase share capital by issuing up to 180,000 new shares. 

Read More
09 May 2017

amp biosimilars AG (Biosilu Healthcare AG) extraordinary general meeting

Frankfurt am Main, May 9, 2017 – amp biosimilars AG (ISIN: DE000A0SMU87, WKN A0SMU8), listed on Munich Stock Exchange’s Open Market, held its extraordinary general meeting on May 8, in Berlin with 72.43 percent of the share capital represented. All management proposals were accepted unanimously.

Read More
03 April 2017

amp biosimilars AG successfully completes cash capital increase

Frankfurt am Main, April 3, 2017 – amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has successfully completed its share capital increase resolved today, with approval of the supervisory board, from EUR 2,050,000.00 to EUR 2,075,000.00 by issuing 25,000 new no-par value bearer shares against cash contribution partially utilizing the existing authorized capital and excluding the shareholders’ subscription rights.

Read More
30 March 2017

amp biosimilars AG adjusts company’s business model

Frankfurt am Main, March 30, 2017 – the management of amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has adjusted the company‘s business model.

Read More
14 March 2017

amp biosimilars AG: Dr Stefan Elßer appointed to the Supervisory Board

On March 14, 2017, Dr Stefan Elßer has appointed by the court of Frankfurt am Main to the Supervisory Board of amp biosimilars AG. Dr Elßer replaces Dr Thomas Zimmer whose term of office ended by the end of the annual general meeting 2016.

Read More
14 September 2016

Umbau des Managements

amp biosimilars AG schließt den planmäßigen Umbau des Managements ab.

Öffnen Sie die PDF-Datei hier.

Read More
01 September 2016

Ordentliche Hauptversammlung der amp biosimilars AG

Alle Beschlussvorschläge der Gesellschaft wurden einstimmig angenommen
 

Öffnen Sie die PDF-Datei hier.

Read More
22 July 2016

Jahresabschluss 2015

Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR.
 

Öffnen Sie die PDF-Datei hier.

Read More
18 July 2016

Änderungen im Vorstand

Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR.
 

Öffnen Sie die PDF-Datei hier.

Read More
28 June 2016

amp biosimilars announces Klaus K. Wilgenbus as new CEO

amp biosimilars AG (ISIN: DE000A0SMU87) today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016.

 

Click the link to download the pdf.

Read More